A5002857933- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Chronic Myeloid Leukemia Treatments
- Epigenetics and DNA Methylation
- Clinical Nutrition and Gastroenterology
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Vascular Tumors and Angiosarcomas
- Bone and Joint Diseases
- Hemoglobinopathies and Related Disorders
- Biomarkers in Disease Mechanisms
- Pituitary Gland Disorders and Treatments
- Hematopoietic Stem Cell Transplantation
- Immune cells in cancer
- Growth Hormone and Insulin-like Growth Factors
- Nanoparticle-Based Drug Delivery
- Lung Cancer Treatments and Mutations
- Iron Metabolism and Disorders
- Angiogenesis and VEGF in Cancer
- Cancer Mechanisms and Therapy
Alexandria University
2009-2025
University of Alabama at Birmingham
2024
Duke University Hospital
2024
Duke Medical Center
2024
Faculty (United Kingdom)
2019
Deoxygenated sickle hemoglobin (HbS) polymerization drives the pathophysiology of cell disease. Therefore, direct inhibition HbS has potential to favorably modify disease outcomes. Voxelotor is an inhibitor.
Acute myeloid leukemia (AML) is a clonal malignant disorder of the bone marrow. Genetic aberrations have an unequivocal role in disease pathogenesis. With application next-generation sequencing technologies (NGS), enormous number genetic fusions and variants has been detected. Their co-occurrence impact on patient`s prognosis. Therefore, our aim this study was to survey fusion genes as well their relation with variants. Targeted following genes, marrow aspirate samples, performed; MECOM,...
Progressive cardiotoxicity following treatment with doxorubicin-based chemotherapy in patients non-Hodgkin's lymphoma (NHL) may lead to late onset cardiomyopathy. So, early prediction of toxicity can prevention heart failure these patients. The aim this work was investigate the role H-FABP as an diagnostic marker anthracycline-induced cardiac together brain natriuretic peptide (BNP) indication ventricular dysfunction such Our study conducted on 40 NHL who received 6 cycles a doxorubicin...
8510^ Background: Panobinostat (PAN) is a potent pan-deacetylase inhibitor that demonstrates synergistic antimyeloma activity when combined with bortezomib (BTZ) + dexamethasone (Dex). Early studies demonstrated durable responses in patients (pts) relapsed (Rel) and relapsed/refractory (RR) multiple myeloma (MM) treated PAN BTZ Dex. This initiated the PANORAMA 1 study, presented herein. Methods: Eligible pts had Rel or RR (excluding BTZ- primary-ref MM) following 1-3 prior regimens. Pts...
Summary Panobinostat in combination with bortezomib and dexamethasone demonstrated a significant clinically meaningful progression‐free survival benefit compared placebo, the phase 3 PANORAMA 1 (Panobinostat Oral Multiple Myeloma 1) trial. Despite this benefit, patients panobinostat arm experienced higher rates of adverse events ( AE s) discontinuation due to s. This subanalysis examined s between 2 treatment phases study TP 2), which administration frequency differed per protocol. The...
Abstract CITE was a prospective, noninterventional study in adult patients with chronic immune thrombocytopenia treated eltrombopag under routine clinical care Asia-Pacific, the Middle East, and Turkey. Data to assess usage, compliance, outcomes were collected from May 2017 December 2020. Platelet response defined as platelet count ≥50 × 103/μL absence of rescue medications splenectomy. Quality life evaluated using Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F)...
8526 Background: Panobinostat (PAN) is a potent pan-deacetylase inhibitor (pan-DACi) that targets key biological aberrations in multiple myeloma (MM), including epigenetics and protein metabolism. PAN + bortezomib (BTZ) dexamethasone (Dex; PAN-BTZ-Dex) led to clinically relevant statistically significant increase progression-free survival (PFS) of ≈4 months compared with placebo BTZ Dex (Pbo-BTZ-Dex) patients (pts) relapsed or refractory MM the PANORAMA 1 phase 3 clinical trial. Methods: The...
Background Acute myeloid leukemia (AML) is a clonal hematopoietic stem cell malignancy characterized by the accumulation of progenitor cells with arrested differentiation, leading to suppression normal hematopoiesis. The disease exhibits significant heterogeneity, less than 30% five-year overall survival. Nucleophosmin 1 (NPM1) most commonly mutated gene in adult AML, found approximately 25–35% patients, and recognized as distinct subtype WHO.
Introduction Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of immature cells. Among genetic alterations in AML, RUNX1- RUNX1T1 fusion, resulting from t (8; 21) (q22; q22.1) translocation, common and linked with favorable prognosis. However, complete mutational profile contributing to leukemogenesis remains unclear. This study characterizes RUNX1-RUNX1T1 fusion AML using Next-Generation Sequencing (NGS).
Histiocytic disorders include a range of uncommon illnesses marked by the buildup cells that have developed into macrophages, dendritic cells, or monocytes in diverse tissues and organs. Over 100 distinct subtypes been documented, exhibiting array clinical symptoms, presentations, histologic features can be confused with other conditions leading to delayed diagnosis. They affect both children adults, generating variety symptoms limited one position, numerous areas within system, many systems...
8575 Background: Panobinostat (PAN) is the first pan-deacetylase inhibitor (pan-DACi) to demonstrate a statistically significant and clinically relevant increase in median progression-free survival (PFS) patients (pts) with relapsed or refractory multiple myeloma (MM) phase 3 clinical trial. In PANORAMA 1 trial, pts randomized receive PAN + bortezomib (BTZ) dexamethasone (Dex; PAN-BTZ-Dex) demonstrated PFS of 12.0 months vs 8.1 for who received placebo BTZ Dex (Pbo-BTZ-Dex; HR, 0.63; P <...